tiprankstipranks
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
US Market
OKUR
OnKure Therapeutics
RESEARCH TOOLSreports

OnKure Therapeutics (OKUR) Stock Forecast & Price Target

436 Followers
See the Price Targets and Ratings of:

OKUR Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
OnKure
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OKUR Stock 12 Month Forecast

Average Price Target

$22.50
▲(413.70% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for OnKure Therapeutics in the last 3 months. The average price target is $22.50 with a high forecast of $30.00 and a low forecast of $16.00. The average price target represents a 413.70% change from the last price of $4.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,6.064615384615385,8.05923076923077,10.053846153846155,12.048461538461538,14.043076923076924,16.03769230769231,18.032307692307693,20.026923076923076,22.021538461538462,24.01615384615385,26.01076923076923,28.005384615384617,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,5.487692307692308,6.905384615384616,8.323076923076922,9.740769230769232,11.158461538461538,12.576153846153845,13.993846153846153,15.411538461538461,16.82923076923077,18.246923076923075,19.664615384615384,21.08230769230769,{"y":22.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,4.987692307692308,5.905384615384616,6.823076923076924,7.7407692307692315,8.658461538461538,9.576153846153847,10.493846153846153,11.411538461538463,12.329230769230769,13.246923076923077,14.164615384615384,15.082307692307692,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$22.50Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on OKUR
Sam Slutsky
LifeSci Capital
LifeSci Capital
$21→$16
Buy
265.30%
Upside
Reiterated
04/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
JonesTrading Analyst forecast on OKUR
Soumit Roy
JonesTrading
JonesTrading
$17
Buy
288.13%
Upside
Reiterated
04/06/26
OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading
H.C. Wainwright Analyst forecast on OKUR
Robert Burns
H.C. Wainwright
H.C. Wainwright
$34→$27
Buy
516.44%
Upside
Reiterated
03/16/26
OnKure Therapeutics price target lowered to $27 from $34 at H.C. WainwrightOnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
Oppenheimer Analyst forecast on OKUR
Matthew Biegler
Oppenheimer
Oppenheimer
$30
Buy
584.93%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (NASDAQ: OKUR) and Verano Holdings (Other OTC: VRNO)
Evercore ISI Analyst forecast on OKUR
Jonathan Miller
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
01/26/26
Evercore ISI Keeps Their Buy Rating on OnKure Therapeutics (OKUR)
Leerink Partners Analyst forecast on OKUR
Andrew Berens
Leerink Partners
Leerink Partners
$33
Buy
653.42%
Upside
Reiterated
08/13/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on OKUR
Sam Slutsky
LifeSci Capital
LifeSci Capital
$21→$16
Buy
265.30%
Upside
Reiterated
04/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
JonesTrading Analyst forecast on OKUR
Soumit Roy
JonesTrading
JonesTrading
$17
Buy
288.13%
Upside
Reiterated
04/06/26
OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading
H.C. Wainwright Analyst forecast on OKUR
Robert Burns
H.C. Wainwright
H.C. Wainwright
$34→$27
Buy
516.44%
Upside
Reiterated
03/16/26
OnKure Therapeutics price target lowered to $27 from $34 at H.C. WainwrightOnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
Oppenheimer Analyst forecast on OKUR
Matthew Biegler
Oppenheimer
Oppenheimer
$30
Buy
584.93%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (NASDAQ: OKUR) and Verano Holdings (Other OTC: VRNO)
Evercore ISI Analyst forecast on OKUR
Jonathan Miller
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
01/26/26
Evercore ISI Keeps Their Buy Rating on OnKure Therapeutics (OKUR)
Leerink Partners Analyst forecast on OKUR
Andrew Berens
Leerink Partners
Leerink Partners
$33
Buy
653.42%
Upside
Reiterated
08/13/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering OnKure Therapeutics

3 Months
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
-12.38%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -12.38% per trade.
1 Year
Soumit RoyJonesTrading
Success Rate
6/9 ratings generated profit
67%
Average Return
+13.92%
Copying Soumit Roy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +13.92% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+18.72%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +18.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OKUR Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
6
5
1
5
6
Buy
0
1
1
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
2
6
6
In the current month, OKUR has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OKUR average Analyst price target in the past 3 months is 22.50.
Each month's total comprises the sum of three months' worth of ratings.

OKUR Financial Forecast

OKUR Earnings Forecast

Next quarter’s earnings estimate for OKUR is -$0.74 with a range of -$1.05 to -$0.39. The previous quarter’s EPS was -$0.99. OKUR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OKUR has Performed in-line its overall industry.
Next quarter’s earnings estimate for OKUR is -$0.74 with a range of -$1.05 to -$0.39. The previous quarter’s EPS was -$0.99. OKUR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OKUR has Performed in-line its overall industry.
No data currently available

OKUR Sales Forecast

Next quarter’s sales forecast for OKUR is $167.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. OKUR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OKUR has Performed in-line its overall industry.
Next quarter’s sales forecast for OKUR is $167.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. OKUR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OKUR has Performed in-line its overall industry.

OKUR Stock Forecast FAQ

What is OKUR’s average 12-month price target, according to analysts?
Based on analyst ratings, OnKure Therapeutics’s 12-month average price target is 22.50.
    What is OKUR’s upside potential, based on the analysts’ average price target?
    OnKure Therapeutics has 413.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OKUR a Buy, Sell or Hold?
          OnKure Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is OnKure Therapeutics’s price target?
            The average price target for OnKure Therapeutics is 22.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $16.00. The average price target represents 413.70% Increase from the current price of $4.38.
              What do analysts say about OnKure Therapeutics?
              OnKure Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of OKUR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.